2-Ethyl-2-methyl-hexanoic acid tert-butyl ester | 66628-79-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2-Ethyl-2-methyl-hexanoic acid tert-butyl ester
• 英文别名: Tert-butyl 2-ethyl-2-methylhexanoate
• CAS: 66628-79-3
• 化学式: C₁₃H₂₆O₂
• 分子量: 214.348
• InChiKey: HEAQZDCCPUUURE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF
  申请人：Si Chuan University

  公开号：US20170305920A1

  公开（公告）日：2017-10-26

  The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.

  本发明涉及化学和药物领域，更具体地涉及3-乙炔吡唑吡嘧啶衍生物及其制备方法和用途。该发明提供了一种3-乙炔吡唑吡嘧啶衍生物，其结构如公式I所示。本发明还提供了3-乙炔吡唑吡嘧啶衍生物的制备方法和用途，包括该化合物和衍生物，以及它们的药物组合物，用于治疗和预防肿瘤。
• 3-acetylenyl-pyrazole-pyrimidine derivative, and preparation method therefor and uses thereof
  申请人：Si Chuan University

  公开号：US10266537B2

  公开（公告）日：2019-04-23

  The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.

  本发明涉及化学和医药领域，尤其是3-乙炔基吡唑嘧啶衍生物及其制备方法和用途。本发明提供了一种 3-乙炔基吡唑嘧啶衍生物，其结构如式 I 所示。本发明还提供了3-乙炔基吡唑嘧啶衍生物的制备方法和用途，包括化合物和衍生物及其药物组合物，用于治疗和预防肿瘤。
• Cyclic peroxides as prodrugs for selective delivery of agents
  申请人：The Regents of the University of California

  公开号：US10287312B2

  公开（公告）日：2019-05-14

  Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

  本文特别公开了原药组合物以及使用原药组合物治疗和检测疾病的方法。具体地说，本文公开了一种具有螺融合 1，2，4-三氧环和哌啶环的式 (I) 化合物，即 1，2，4-三氧杂-8-氮杂螺[4.5]癸烷。还公开了一种药物组合物，其中含有该化合物和一种药学上可接受的载体。
• Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
  申请人：Hyundai Pharm Co., Ltd.

  公开号：US10723699B2

  公开（公告）日：2020-07-28

  The present invention relates to a cyclohexene derivative, a preparation method thereof, and a pharmaceutical composition for preventing or treating metabolic disease containing the cyclohexene derivative as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

  本发明涉及一种环己烯衍生物、其制备方法以及一种含有该环己烯衍生物作为活性成分的预防或治疗代谢性疾病的药物组合物。根据本发明的环己烯衍生物通过激活 G 蛋白偶联受体 119（GPR-119）来增加细胞内环磷酸腺苷（cAMP）的活性，同时通过诱导胰高血糖素样肽-1（GLP-1）的释放来表现出减肥和降血糖的效果、GLP-1 是一种神经内分泌蛋白，因此可作为药物组合物用于预防或治疗代谢性疾病，如肥胖、1 型糖尿病、2 型糖尿病、糖耐量不足、胰岛素抵抗、高血糖、高脂血症、高甘油三酯血症、高胆固醇血症、血脂异常和 X 综合征。
• Small molecule antagonists of sumo related modification of CRMP2 and uses thereof
  申请人：Arizona Board of Regents on Behalf of the University of Arizona

  公开号：US11208397B2

  公开（公告）日：2021-12-28

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

  本发明属于药物化学领域。特别是，本发明涉及一类具有哌啶基苯并咪唑结构的新的小分子，它们可作为塌缩素反应介质蛋白 2（CRMP2）的小泛素样修饰剂（SUMO）相关修饰（SUMOylation）的拮抗剂，并可用作治疗与电压门控钠通道 1.7（Nav1.7）相关的痒、嗅觉障碍、偏头痛事件和/或疼痛（如神经性疼痛）的药物。